DK1512686T3 - Imidazonaphtyridiner og deres anvendelse til at inducere cytokinbiosyntese - Google Patents
Imidazonaphtyridiner og deres anvendelse til at inducere cytokinbiosynteseInfo
- Publication number
- DK1512686T3 DK1512686T3 DK04022441T DK04022441T DK1512686T3 DK 1512686 T3 DK1512686 T3 DK 1512686T3 DK 04022441 T DK04022441 T DK 04022441T DK 04022441 T DK04022441 T DK 04022441T DK 1512686 T3 DK1512686 T3 DK 1512686T3
- Authority
- DK
- Denmark
- Prior art keywords
- compounds
- imidazonaphtyridines
- cytokine biosynthesis
- induce cytokine
- biosynthesis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- AIDS & HIV (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6927697P | 1997-12-11 | 1997-12-11 | |
| PCT/US1998/026473 WO1999029693A1 (en) | 1997-12-11 | 1998-12-11 | Imidazonaphthyridines and their use in inducing cytokine biosynthesis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1512686T3 true DK1512686T3 (da) | 2007-01-15 |
Family
ID=22087889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK04022441T DK1512686T3 (da) | 1997-12-11 | 1998-12-11 | Imidazonaphtyridiner og deres anvendelse til at inducere cytokinbiosyntese |
Country Status (28)
Families Citing this family (223)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5741908A (en) | 1996-06-21 | 1998-04-21 | Minnesota Mining And Manufacturing Company | Process for reparing imidazoquinolinamines |
| UA67760C2 (uk) | 1997-12-11 | 2004-07-15 | Міннесота Майнінг Енд Мануфакчурінг Компані | Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки |
| US6518280B2 (en) | 1998-12-11 | 2003-02-11 | 3M Innovative Properties Company | Imidazonaphthyridines |
| EP1140091B1 (en) | 1999-01-08 | 2005-09-21 | 3M Innovative Properties Company | Formulations comprising imiquimod or other immune response modifiers for treating cervical dysplasia |
| US20020058674A1 (en) | 1999-01-08 | 2002-05-16 | Hedenstrom John C. | Systems and methods for treating a mucosal surface |
| US6486168B1 (en) | 1999-01-08 | 2002-11-26 | 3M Innovative Properties Company | Formulations and methods for treatment of mucosal associated conditions with an immune response modifier |
| US6558951B1 (en) * | 1999-02-11 | 2003-05-06 | 3M Innovative Properties Company | Maturation of dendritic cells with immune response modifying compounds |
| SI1198233T1 (sl) * | 1999-06-10 | 2007-02-28 | 3M Innovative Properties Co | S sulfonamidom in sulfamidom substituirani imidazokinolini |
| US6451810B1 (en) * | 1999-06-10 | 2002-09-17 | 3M Innovative Properties Company | Amide substituted imidazoquinolines |
| US6756382B2 (en) * | 1999-06-10 | 2004-06-29 | 3M Innovative Properties Company | Amide substituted imidazoquinolines |
| US6331539B1 (en) | 1999-06-10 | 2001-12-18 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
| US6541485B1 (en) | 1999-06-10 | 2003-04-01 | 3M Innovative Properties Company | Urea substituted imidazoquinolines |
| EP1438958A1 (en) * | 1999-06-10 | 2004-07-21 | 3M Innovative Properties Company | Carbamate substituted imidazoquinolines |
| US6573273B1 (en) | 1999-06-10 | 2003-06-03 | 3M Innovative Properties Company | Urea substituted imidazoquinolines |
| US6916925B1 (en) | 1999-11-05 | 2005-07-12 | 3M Innovative Properties Co. | Dye labeled imidazoquinoline compounds |
| US6376669B1 (en) | 1999-11-05 | 2002-04-23 | 3M Innovative Properties Company | Dye labeled imidazoquinoline compounds |
| JP3436512B2 (ja) * | 1999-12-28 | 2003-08-11 | 株式会社デンソー | アクセル装置 |
| US6894060B2 (en) | 2000-03-30 | 2005-05-17 | 3M Innovative Properties Company | Method for the treatment of dermal lesions caused by envenomation |
| US20040209877A1 (en) * | 2000-04-13 | 2004-10-21 | Shelby Nancy J. | Methods for augmenting immune defenses contemplating the administration of phenolic and indoleamine-like compounds for use in animals ans humans |
| UA74593C2 (en) * | 2000-12-08 | 2006-01-16 | 3M Innovative Properties Co | Substituted imidazopyridines |
| US6667312B2 (en) * | 2000-12-08 | 2003-12-23 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
| AU2006216669A1 (en) * | 2000-12-08 | 2006-08-31 | 3M Innovative Properties Company | Compositions and methods for targeted delivery of immune response modifiers |
| US6545017B1 (en) * | 2000-12-08 | 2003-04-08 | 3M Innovative Properties Company | Urea substituted imidazopyridines |
| US6664264B2 (en) * | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
| US6545016B1 (en) * | 2000-12-08 | 2003-04-08 | 3M Innovative Properties Company | Amide substituted imidazopyridines |
| US6660747B2 (en) | 2000-12-08 | 2003-12-09 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
| US6677348B2 (en) | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Aryl ether substituted imidazoquinolines |
| AU3249802A (en) * | 2000-12-08 | 2002-06-18 | 3M Innovative Properties Co | Screening method for identifying compounds that selectively induce interferon alpha |
| US6677347B2 (en) * | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamido ether substituted imidazoquinolines |
| UA74852C2 (en) * | 2000-12-08 | 2006-02-15 | 3M Innovative Properties Co | Urea-substituted imidazoquinoline ethers |
| US6525064B1 (en) | 2000-12-08 | 2003-02-25 | 3M Innovative Properties Company | Sulfonamido substituted imidazopyridines |
| US6664260B2 (en) * | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Heterocyclic ether substituted imidazoquinolines |
| US6664265B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
| US6660735B2 (en) * | 2000-12-08 | 2003-12-09 | 3M Innovative Properties Company | Urea substituted imidazoquinoline ethers |
| US7226928B2 (en) * | 2001-06-15 | 2007-06-05 | 3M Innovative Properties Company | Methods for the treatment of periodontal disease |
| WO2003020889A2 (en) * | 2001-08-30 | 2003-03-13 | 3M Innovative Properties Company | Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules |
| US20040014779A1 (en) * | 2001-11-16 | 2004-01-22 | 3M Innovative Properties Company | Methods and compositions related to IRM compounds and toll-like recptor pathways |
| CA2467828C (en) * | 2001-11-29 | 2011-10-04 | 3M Innovative Properties Company | Pharmaceutical formulations comprising an immune response modifier |
| CA2365732A1 (en) * | 2001-12-20 | 2003-06-20 | Ibm Canada Limited-Ibm Canada Limitee | Testing measurements |
| US6677349B1 (en) * | 2001-12-21 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
| SI1478327T1 (sl) * | 2002-02-22 | 2015-08-31 | Meda Ab | Metoda za zmanjšanje in zdravljenje imunosupresije, inducirane z UV-B |
| AU2003237386A1 (en) | 2002-06-07 | 2003-12-22 | 3M Innovative Properties Company | Ether substituted imidazopyridines |
| WO2004032829A2 (en) | 2002-08-15 | 2004-04-22 | 3M Innovative Properties Company | Immunostimulatory compositions and methods of stimulating an immune response |
| US6818650B2 (en) * | 2002-09-26 | 2004-11-16 | 3M Innovative Properties Company | 1H-imidazo dimers |
| AU2003287316A1 (en) * | 2002-12-11 | 2004-06-30 | 3M Innovative Properties Company | Assays relating to toll-like receptor activity |
| AU2003287324A1 (en) * | 2002-12-11 | 2004-06-30 | 3M Innovative Properties Company | Gene expression systems and recombinant cell lines |
| EP1590348A1 (en) | 2002-12-20 | 2005-11-02 | 3M Innovative Properties Company | Aryl / hetaryl substituted imidazoquinolines |
| JP2006512391A (ja) | 2002-12-30 | 2006-04-13 | スリーエム イノベイティブ プロパティズ カンパニー | 組み合わせ免疫賦活薬 |
| WO2004071459A2 (en) * | 2003-02-13 | 2004-08-26 | 3M Innovative Properties Company | Methods and compositions related to irm compounds and toll-like receptor 8 |
| EP1599726A4 (en) * | 2003-02-27 | 2009-07-22 | 3M Innovative Properties Co | SELECTIVE MODULATION OF TLR-MEDIATED BIOLOGICAL ACTIVITY |
| AU2004218349A1 (en) | 2003-03-04 | 2004-09-16 | 3M Innovative Properties Company | Prophylactic treatment of UV-induced epidermal neoplasia |
| CA2517655A1 (en) * | 2003-03-07 | 2004-09-23 | 3M Innovative Properties Company | 1-amino 1h-imidazoquinolines |
| US7163947B2 (en) * | 2003-03-07 | 2007-01-16 | 3M Innovative Properties Company | 1-Amino 1H-imidazoquinolines |
| US8426457B2 (en) * | 2003-03-13 | 2013-04-23 | Medicis Pharmaceutical Corporation | Methods of improving skin quality |
| US7699057B2 (en) * | 2003-03-13 | 2010-04-20 | 3M Innovative Properties Company | Methods for treating skin lesions |
| AU2004220465A1 (en) | 2003-03-13 | 2004-09-23 | 3M Innovative Properties Company | Method of tattoo removal |
| US20040192585A1 (en) | 2003-03-25 | 2004-09-30 | 3M Innovative Properties Company | Treatment for basal cell carcinoma |
| ES2423800T3 (es) | 2003-03-28 | 2013-09-24 | Novartis Vaccines And Diagnostics, Inc. | Uso de compuestos orgánicos para la inmunopotenciación |
| AU2004244962A1 (en) * | 2003-04-10 | 2004-12-16 | 3M Innovative Properties Company | Delivery of immune response modifier compounds using metal-containing particulate support materials |
| US20040265351A1 (en) * | 2003-04-10 | 2004-12-30 | Miller Richard L. | Methods and compositions for enhancing immune response |
| EP1617845A4 (en) * | 2003-04-28 | 2006-09-20 | 3M Innovative Properties Co | COMPOSITIONS AND METHODS FOR INDUCING OPOID RECEPTORS |
| US7731967B2 (en) | 2003-04-30 | 2010-06-08 | Novartis Vaccines And Diagnostics, Inc. | Compositions for inducing immune responses |
| US7176214B2 (en) | 2003-05-21 | 2007-02-13 | Bristol-Myers Squibb Company | Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same |
| US20050032829A1 (en) * | 2003-06-06 | 2005-02-10 | 3M Innovative Properties Company | Process for imidazo[4,5-c]pyridin-4-amines |
| US6943255B2 (en) * | 2003-06-06 | 2005-09-13 | 3M Innovative Properties Company | Process for imidazo[4,5-c]pyridin-4-amines |
| WO2005012488A2 (en) * | 2003-07-31 | 2005-02-10 | 3M Innovative Properties Company | Compositions for encapsulation and controlled release |
| WO2005016275A2 (en) * | 2003-08-05 | 2005-02-24 | 3M Innovative Properties Company | Formulations containing an immune response modifier |
| WO2005018556A2 (en) * | 2003-08-12 | 2005-03-03 | 3M Innovative Properties Company | Hydroxylamine substituted imidazo-containing compounds |
| AU2004266657B2 (en) | 2003-08-14 | 2009-07-02 | 3M Innovative Properties Company | Lipid-modified immune response modifiers |
| JP4913593B2 (ja) * | 2003-08-14 | 2012-04-11 | スリーエム イノベイティブ プロパティズ カンパニー | 脂質修飾された免疫応答調整剤 |
| CA2551075A1 (en) * | 2003-08-25 | 2005-03-03 | 3M Innovative Properties Company | Immunostimulatory combinations and treatments |
| JP2007503268A (ja) * | 2003-08-25 | 2007-02-22 | スリーエム イノベイティブ プロパティズ カンパニー | 免疫応答修飾化合物の送達 |
| ES2406730T3 (es) | 2003-08-27 | 2013-06-07 | 3M Innovative Properties Company | Imidazoquinolinas sustituidas con ariloxi y arilalquilenoxi |
| EP1663222A4 (en) * | 2003-09-02 | 2008-05-21 | 3M Innovative Properties Co | METHODS RELATING TO THE TREATMENT OF GIANCES |
| AU2004270201A1 (en) | 2003-09-05 | 2005-03-17 | 3M Innovative Properties Company | Treatment for CD5+ B cell lymphoma |
| CA2536530A1 (en) | 2003-10-01 | 2005-04-14 | Taro Pharmaceuticals U.S.A., Inc. | Method of preparing 4-amino-1h-imidazo(4,5-c)quinolines and acid addition salts thereof |
| US20090075980A1 (en) * | 2003-10-03 | 2009-03-19 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and Analogs Thereof |
| CA2540541C (en) | 2003-10-03 | 2012-03-27 | 3M Innovative Properties Company | Alkoxy substituted imidazoquinolines |
| CA2540598C (en) | 2003-10-03 | 2013-09-24 | 3M Innovative Properties Company | Pyrazolopyridines and analogs thereof |
| US7544697B2 (en) * | 2003-10-03 | 2009-06-09 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and analogs thereof |
| EP1680080A4 (en) * | 2003-10-31 | 2007-10-31 | 3M Innovative Properties Co | NEUTROPHILIC ACTIVATION THROUGH COMPOUNDS TO MODIFY THE IMMUNE RESPONSE |
| WO2005048945A2 (en) | 2003-11-14 | 2005-06-02 | 3M Innovative Properties Company | Hydroxylamine substituted imidazo ring compounds |
| EP1685129A4 (en) * | 2003-11-14 | 2008-10-22 | 3M Innovative Properties Co | OXIMSUBSTITUTED IMIDAZORING CONNECTIONS |
| EP1686992A4 (en) * | 2003-11-25 | 2009-11-04 | 3M Innovative Properties Co | HYDROXYLAMINE, AND IMIDAZOQUINOLEINS, AND IMIDAZOPYRIDINES AND IMIDAZONAPHTYRIDINE SUBSTITUTED WITH OXIME |
| JP4891088B2 (ja) | 2003-11-25 | 2012-03-07 | スリーエム イノベイティブ プロパティズ カンパニー | 置換されたイミダゾ環系および方法 |
| US8940755B2 (en) * | 2003-12-02 | 2015-01-27 | 3M Innovative Properties Company | Therapeutic combinations and methods including IRM compounds |
| US20050226878A1 (en) * | 2003-12-02 | 2005-10-13 | 3M Innovative Properties Company | Therapeutic combinations and methods including IRM compounds |
| AR048289A1 (es) * | 2003-12-04 | 2006-04-19 | 3M Innovative Properties Co | Eteres de anillos imidazo sulfona sustituidos. |
| JP2007517035A (ja) * | 2003-12-29 | 2007-06-28 | スリーエム イノベイティブ プロパティズ カンパニー | アリールアルケニルおよびアリールアルキニル置換されたイミダゾキノリン |
| WO2005066172A1 (en) * | 2003-12-29 | 2005-07-21 | 3M Innovative Properties Company | Piperazine, [1,4]diazepane, [1,4]diazocane, and [1,5]diazocane fused imidazo ring compounds |
| US20050239735A1 (en) * | 2003-12-30 | 2005-10-27 | 3M Innovative Properties Company | Enhancement of immune responses |
| CA2551399A1 (en) * | 2003-12-30 | 2005-07-21 | 3M Innovative Properties Company | Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides |
| ES2665342T3 (es) | 2004-03-15 | 2018-04-25 | Meda Ab | Formulaciones y métodos para modificadores de la respuesta inmune |
| CA2559863A1 (en) * | 2004-03-24 | 2005-10-13 | 3M Innovative Properties Company | Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines |
| AU2005244260B2 (en) * | 2004-04-09 | 2010-08-05 | 3M Innovative Properties Company | Methods, compositions, and preparations for delivery of immune response modifiers |
| CN101426524A (zh) * | 2004-04-28 | 2009-05-06 | 3M创新有限公司 | 用于粘膜接种疫苗的组合物和方法 |
| US20050267145A1 (en) * | 2004-05-28 | 2005-12-01 | Merrill Bryon A | Treatment for lung cancer |
| US20080015184A1 (en) * | 2004-06-14 | 2008-01-17 | 3M Innovative Properties Company | Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines |
| US8017779B2 (en) | 2004-06-15 | 2011-09-13 | 3M Innovative Properties Company | Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines |
| WO2006038923A2 (en) * | 2004-06-18 | 2006-04-13 | 3M Innovative Properties Company | Aryl substituted imidazonaphthyridines |
| US8026366B2 (en) | 2004-06-18 | 2011-09-27 | 3M Innovative Properties Company | Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines |
| JP5128940B2 (ja) * | 2004-06-18 | 2013-01-23 | スリーエム イノベイティブ プロパティズ カンパニー | 置換イミダゾキノリン、イミダゾピリジン、およびイミダゾナフチリジン |
| WO2006009832A1 (en) * | 2004-06-18 | 2006-01-26 | 3M Innovative Properties Company | Substituted imidazo ring systems and methods |
| US8541438B2 (en) | 2004-06-18 | 2013-09-24 | 3M Innovative Properties Company | Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines |
| US7915281B2 (en) | 2004-06-18 | 2011-03-29 | 3M Innovative Properties Company | Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method |
| US20110104186A1 (en) | 2004-06-24 | 2011-05-05 | Nicholas Valiante | Small molecule immunopotentiators and assays for their detection |
| CA2571421A1 (en) | 2004-06-24 | 2006-01-05 | Nicholas Valiante | Compounds for immunopotentiation |
| EP1786450A4 (en) * | 2004-08-27 | 2009-11-11 | 3M Innovative Properties Co | HIV IMMUNOSTIMATORY COMPOSITIONS |
| WO2006026760A2 (en) * | 2004-09-02 | 2006-03-09 | 3M Innovative Properties Company | 1-amino imidazo-containing compounds and methods |
| WO2006029115A2 (en) * | 2004-09-02 | 2006-03-16 | 3M Innovative Properties Company | 2-amino 1h imidazo ring systems and methods |
| JP5209312B2 (ja) * | 2004-09-02 | 2013-06-12 | スリーエム イノベイティブ プロパティズ カンパニー | １−アルコキシ１ｈ−イミダゾ環系および方法 |
| US20080193468A1 (en) * | 2004-09-08 | 2008-08-14 | Children's Medical Center Corporation | Method for Stimulating the Immune Response of Newborns |
| US20070243215A1 (en) * | 2004-10-08 | 2007-10-18 | Miller Richard L | Adjuvant for Dna Vaccines |
| WO2006053166A1 (en) * | 2004-11-12 | 2006-05-18 | Bristol-Myers Squibb Company | 8h-imidazo[4,5-d]thiazolo[4,5-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same |
| ATE538124T1 (de) | 2004-11-12 | 2012-01-15 | Bristol Myers Squibb Co | Imidazokondensierte tricyclische verbindungen auf thiazoloä4,5-büpyridin-basis und pharmazeutische zusammensetzungen damit |
| WO2006063072A2 (en) * | 2004-12-08 | 2006-06-15 | 3M Innovative Properties Company | Immunomodulatory compositions, combinations and methods |
| US8080560B2 (en) * | 2004-12-17 | 2011-12-20 | 3M Innovative Properties Company | Immune response modifier formulations containing oleic acid and methods |
| AU2005321912B2 (en) | 2004-12-30 | 2012-04-05 | 3M Innovative Properties Company | Treatment for cutaneous metastases |
| AU2005326708C1 (en) | 2004-12-30 | 2012-08-30 | 3M Innovative Properties Company | Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds |
| US8436176B2 (en) * | 2004-12-30 | 2013-05-07 | Medicis Pharmaceutical Corporation | Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine |
| AU2005322898B2 (en) * | 2004-12-30 | 2011-11-24 | 3M Innovative Properties Company | Chiral fused (1,2)imidazo(4,5-c) ring compounds |
| AR052447A1 (es) * | 2004-12-30 | 2007-03-21 | 3M Innovative Properties Co | Etansulfonato de 1-(2-metipropil)-1h-imidazo[4,5-c] [1,5] naftiridin-4- amina y metansulfonato de 1-(2- metipropil)-1h-imidazo[4,5 -c] [1,5] naftiridin-4-amina |
| EA200701584A1 (ru) | 2005-01-27 | 2008-02-28 | Альма Матер Студиорум - Университа' Ди Болонья | Органические соединения, применяемые для лечения болезни альцгеймера, их применение и способ получения |
| CA2597092A1 (en) | 2005-02-04 | 2006-08-10 | Coley Pharmaceutical Group, Inc. | Aqueous gel formulations containing immune reponse modifiers |
| US20080318998A1 (en) * | 2005-02-09 | 2008-12-25 | Coley Pharmaceutical Group, Inc. | Alkyloxy Substituted Thiazoloquinolines and Thiazolonaphthyridines |
| AU2006338521A1 (en) | 2005-02-09 | 2007-10-11 | Coley Pharmaceutical Group, Inc. | Oxime and hydroxylamine substituted thiazolo(4,5-c) ring compounds and methods |
| US8658666B2 (en) * | 2005-02-11 | 2014-02-25 | 3M Innovative Properties Company | Substituted imidazoquinolines and imidazonaphthyridines |
| WO2006086634A2 (en) | 2005-02-11 | 2006-08-17 | Coley Pharmaceutical Group, Inc. | Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods |
| CA2598639A1 (en) * | 2005-02-23 | 2006-08-31 | Coley Pharmaceutical Group, Inc. | Hydroxyalkyl substituted imidazonaphthyridines |
| JP2008538203A (ja) * | 2005-02-23 | 2008-10-16 | コーリー ファーマシューティカル グループ，インコーポレイテッド | インターフェロンの生合成を優先的に誘導する方法 |
| AU2006216798A1 (en) * | 2005-02-23 | 2006-08-31 | Coley Pharmaceutical Group, Inc. | Hydroxyalkyl substituted imidazoquinoline compounds and methods |
| EP1851224A2 (en) * | 2005-02-23 | 2007-11-07 | 3M Innovative Properties Company | Hydroxyalkyl substituted imidazoquinolines |
| CA2602098A1 (en) * | 2005-03-14 | 2006-09-21 | Graceway Pharmaceuticals, Llc | Method of treating actinic keratosis |
| AU2006244635A1 (en) * | 2005-04-01 | 2006-11-16 | Coley Pharmaceutical Group, Inc. | Ring closing and related methods and intermediates |
| EP1869043A2 (en) | 2005-04-01 | 2007-12-26 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridine-1,4-diamines and analogs thereof |
| CA2602590A1 (en) | 2005-04-01 | 2006-10-12 | Coley Pharmaceutical Group, Inc. | 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases |
| US20080193474A1 (en) * | 2005-04-25 | 2008-08-14 | Griesgraber George W | Immunostimulatory Compositions |
| US20080234318A1 (en) * | 2005-08-31 | 2008-09-25 | Kristjan Gudmundsson | Chemical Compounds |
| JP2009507856A (ja) * | 2005-09-09 | 2009-02-26 | コーリー ファーマシューティカル グループ，インコーポレイテッド | Ｎ−｛２−［４−アミノ−２−（エトキシメチル）−１Ｈ−イミダゾ［４，５−ｃ］キノリン−１−イル］−１，１−ジメチルエチル｝メタンスルホンアミドのアミドおよびカルバマート誘導体ならびに方法 |
| ZA200803029B (en) * | 2005-09-09 | 2009-02-25 | Coley Pharm Group Inc | Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods |
| US8889154B2 (en) | 2005-09-15 | 2014-11-18 | Medicis Pharmaceutical Corporation | Packaging for 1-(2-methylpropyl)-1H-imidazo[4,5-c] quinolin-4-amine-containing formulation |
| JP5247458B2 (ja) * | 2005-11-04 | 2013-07-24 | スリーエム・イノベイティブ・プロパティーズ・カンパニー | ヒドロキシ及びアルコキシ置換１ｈ−イミダゾキノリン及び方法 |
| WO2007079086A1 (en) * | 2005-12-28 | 2007-07-12 | Coley Pharmaceutical Group, Inc. | Pyrazoloalkyl substituted imidazo ring compounds and methods |
| US8951528B2 (en) * | 2006-02-22 | 2015-02-10 | 3M Innovative Properties Company | Immune response modifier conjugates |
| WO2007106854A2 (en) * | 2006-03-15 | 2007-09-20 | Coley Pharmaceutical Group, Inc. | Hydroxy and alkoxy substituted 1h-imidazonaphthyridines and methods |
| US8088788B2 (en) | 2006-03-15 | 2012-01-03 | 3M Innovative Properties Company | Substituted fused[1,2] imidazo[4,5-c] ring compounds and methods |
| EP2357184B1 (en) | 2006-03-23 | 2015-02-25 | Novartis AG | Imidazoquinoxaline compounds as immunomodulators |
| WO2007143526A2 (en) * | 2006-06-05 | 2007-12-13 | Coley Pharmaceutical Group, Inc. | Substituted tetrahydroimidazonaphthyridines and methods |
| WO2008008432A2 (en) * | 2006-07-12 | 2008-01-17 | Coley Pharmaceutical Group, Inc. | Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods |
| WO2008010963A2 (en) * | 2006-07-18 | 2008-01-24 | 3M Innovative Properties Company | Immune response modifier formulations |
| WO2008016475A2 (en) * | 2006-07-31 | 2008-02-07 | 3M Innovative Properties Company | Immune response modifier compositions and methods |
| WO2008030511A2 (en) * | 2006-09-06 | 2008-03-13 | Coley Pharmaceuticial Group, Inc. | Substituted 3,4,6,7-tetrahydro-5h, 1,2a,4a,8-tetraazacyclopenta[cd]phenalenes |
| US20080149123A1 (en) * | 2006-12-22 | 2008-06-26 | Mckay William D | Particulate material dispensing hairbrush with combination bristles |
| JP2010514679A (ja) * | 2006-12-22 | 2010-05-06 | スリーエム イノベイティブ プロパティズ カンパニー | 制御放出組成物及び方法 |
| WO2008098232A1 (en) * | 2007-02-08 | 2008-08-14 | Graceway Pharmaceuticals, Llc | Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy |
| US20100160368A1 (en) * | 2008-08-18 | 2010-06-24 | Gregory Jefferson J | Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy |
| EP2378876B1 (en) | 2008-12-19 | 2018-11-14 | Medicis Pharmaceutical Corporation | Lower dosage strength imiquimod formulations and short dosing regimens for treating actinic keratosis |
| EP2411521B1 (en) | 2009-03-25 | 2015-01-14 | The Board of Regents of The University of Texas System | Compositions for stimulation of mammalian innate immune resistance to pathogens |
| US8349827B2 (en) * | 2009-03-31 | 2013-01-08 | Arqule, Inc. | Substituted dipyrido-pyrimido-diazepine and benzo-pyrido-pyrimido compounds |
| US8511006B2 (en) * | 2009-07-02 | 2013-08-20 | Owens Corning Intellectual Capital, Llc | Building-integrated solar-panel roof element systems |
| AU2010274097B2 (en) | 2009-07-13 | 2016-06-16 | Medicis Pharmaceutical Corporation | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts |
| US20110033515A1 (en) * | 2009-08-04 | 2011-02-10 | Rst Implanted Cell Technology | Tissue contacting material |
| TW201129565A (en) * | 2010-01-12 | 2011-09-01 | Hoffmann La Roche | Tricyclic heterocyclic compounds, compositions and methods of use thereof |
| WO2011163617A1 (en) | 2010-06-25 | 2011-12-29 | Graceway Pharmaceuticals, Llc | Combination therapy with cryosurgery and low dosage strength imiquimod to treat actinic keratosis |
| HUE033901T2 (en) | 2010-08-17 | 2018-01-29 | 3M Innovative Properties Co | Formulations and formulations for lipidized immune response modifying compounds and related processes |
| JP6415979B2 (ja) | 2011-06-03 | 2018-10-31 | スリーエム イノベイティブ プロパティズ カンパニー | ヒドラジノ１ｈ−イミダゾキノリン−４−アミン及びこれから調製された複合体 |
| CA2838158C (en) | 2011-06-03 | 2019-07-16 | 3M Innovative Properties Company | Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom |
| US20130023736A1 (en) | 2011-07-21 | 2013-01-24 | Stanley Dale Harpstead | Systems for drug delivery and monitoring |
| WO2013040447A2 (en) | 2011-09-14 | 2013-03-21 | Medicis Pharmaceutical Corporation | Combination therapy with low dosage strength imiquimod and photodynamic therapy to treat actinic keratosis |
| ES2727481T3 (es) | 2011-11-30 | 2019-10-16 | Sarepta Therapeutics Inc | Inclusión inducida de exón en atrofia muscular espinal |
| US10076535B2 (en) | 2012-04-27 | 2018-09-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of CPG oligonucleotides co-formulated with an antibiotic to accelerate wound healing |
| MX359257B (es) | 2012-05-04 | 2018-09-19 | Pfizer | Antígenos asociados a próstata y regímenes de inmunoterapia basados en vacuna. |
| CN112587658A (zh) | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
| HUE051988T2 (hu) | 2013-01-07 | 2021-04-28 | Univ Pennsylvania | Készítmények és eljárások bõr T-sejt lymphoma kezelésére |
| EP3632458A1 (en) | 2013-07-26 | 2020-04-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of bacterial infections |
| EP3065741B1 (en) | 2013-11-05 | 2021-09-22 | 3M Innovative Properties Company | Sesame oil based injection formulations |
| CA2933767C (en) | 2013-12-17 | 2018-11-06 | Pfizer Inc. | Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors |
| CN105899539B (zh) | 2014-01-10 | 2021-11-09 | 博笛生物科技有限公司 | 用于免疫疗法的化合物和组合物 |
| EP4001311A1 (en) | 2014-07-09 | 2022-05-25 | Birdie Biopharmaceuticals Inc. | Anti-pd-l1 combinations for treating tumors |
| CN112546230A (zh) | 2014-07-09 | 2021-03-26 | 博笛生物科技有限公司 | 用于治疗癌症的联合治疗组合物和联合治疗方法 |
| CN105440135A (zh) | 2014-09-01 | 2016-03-30 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1结合物 |
| WO2016180852A1 (en) | 2015-05-12 | 2016-11-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for preparing antigen-specific t cells from an umbilical cord blood sample |
| US11680244B2 (en) | 2015-05-20 | 2023-06-20 | The Regents Of The University Of California | Method for generating human dendritic cells for immunotherapy |
| US10118925B2 (en) | 2015-08-31 | 2018-11-06 | 3M Innovative Properties Company | Imidazo[4,5-c] ring compounds containing substituted guanidine groups |
| AU2016317637B2 (en) | 2015-08-31 | 2019-01-31 | Solventum Intellectual Properties Company | Guanidine substituted imidazo[4,5-c] ring compounds |
| CN108137586B (zh) | 2015-09-14 | 2021-04-13 | 辉瑞大药厂 | 作为LRRK2抑制剂的新颖咪唑并[4,5-c]喹啉和咪唑并[4,5-c][1,5]萘啶衍生物 |
| WO2017059280A1 (en) | 2015-10-02 | 2017-04-06 | The University Of North Carolina At Chapel Hill | Novel pan-tam inhibitors and mer/axl dual inhibitors |
| CN115350279A (zh) | 2016-01-07 | 2022-11-18 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-her2组合 |
| CN106943596A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技（北京）有限公司 | 用于治疗肿瘤的抗-cd20组合 |
| CN106943597A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技（北京）有限公司 | 用于治疗肿瘤的抗-egfr组合 |
| JP6883806B2 (ja) * | 2016-03-09 | 2021-06-09 | 国立大学法人大阪大学 | 化合物、及びこれを含む有機半導体材料 |
| CN109562057A (zh) | 2016-05-16 | 2019-04-02 | 传染病研究所 | 聚乙二醇化脂质体和使用方法 |
| IL314130A (en) | 2016-05-16 | 2024-09-01 | Access To Advanced Health Inst | Formulation containing a TLR agonist and methods of use |
| EP3504215B1 (en) | 2016-08-26 | 2022-04-06 | 3M Innovative Properties Company | Fused [1,2]imidazo[4,5-c]ring compounds substituted with guanidino groups |
| CA3033542A1 (en) | 2016-08-30 | 2018-03-08 | Dana-Farber Cancer Institute, Inc. | Compositions and uses of biomaterials and activators of innate immunity |
| IL266562B1 (en) | 2016-11-09 | 2024-07-01 | Univ Texas | Pharmaceutical compositions for immune regulation adapted for use in the patient sensitive to allergen-induced asthma |
| US11426566B2 (en) | 2016-12-14 | 2022-08-30 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with a TLR modulator |
| AU2017378398B2 (en) | 2016-12-14 | 2023-02-02 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with a JAK inhibitor and devices |
| CA3045475A1 (en) | 2016-12-14 | 2018-06-21 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor released using an ingestible device |
| CA3045472A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a smad7 inhibitor |
| EP3554346B1 (en) | 2016-12-14 | 2024-01-31 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with an immunosuppressant |
| CA3045310A1 (en) | 2016-12-14 | 2018-06-21 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
| WO2018160552A1 (en) | 2017-03-01 | 2018-09-07 | 3M Innovative Properties Company | IMIDAZO[4,5-c] RING COMPOUNDS CONTAINING GUANIDINE SUBSTITUTED BENZAMIDE GROUPS |
| US11596670B2 (en) | 2017-03-30 | 2023-03-07 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with IL-10 or an IL-10 agonist |
| CN118515666A (zh) | 2017-04-27 | 2024-08-20 | 博笛生物科技有限公司 | 2-氨基-喹啉衍生物 |
| AR111760A1 (es) | 2017-05-19 | 2019-08-14 | Novartis Ag | Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral |
| JP7080501B2 (ja) | 2017-06-23 | 2022-06-06 | バーディー バイオファーマシューティカルズ インコーポレイテッド | 医薬品組成物 |
| EP4257198A3 (en) | 2017-08-22 | 2023-10-18 | Dynavax Technologies Corporation | Alkyl chain modified imidazoquinoline derivatives as tlr7/8 agonists and uses thereof |
| JP2021503005A (ja) | 2017-11-14 | 2021-02-04 | ダイナバックス テクノロジーズ コーポレイション | Ｔｌｒ７／８アゴニスト化合物の切断可能なコンジュゲート、その調製方法および使用 |
| JP7197244B2 (ja) | 2017-12-20 | 2022-12-27 | スリーエム イノベイティブ プロパティズ カンパニー | 免疫応答調節剤として使用するための分岐鎖連結基を有するアミド置換イミダゾ［４，５－ｃ］キノリン化合物 |
| JP7251893B2 (ja) | 2018-02-28 | 2023-04-04 | スリーエム イノベイティブ プロパティズ カンパニー | Ｎ－１分枝基を有する置換イミダゾ［４，５－ｃ］キノリン化合物 |
| SG11202007518RA (en) | 2018-02-28 | 2020-09-29 | Pfizer | Il-15 variants and uses thereof |
| SG11202010580TA (en) | 2018-05-23 | 2020-12-30 | Pfizer | Antibodies specific for cd3 and uses thereof |
| KR102584675B1 (ko) | 2018-05-23 | 2023-10-05 | 화이자 인코포레이티드 | GUCY2c에 특이적인 항체 및 이의 용도 |
| CA3101277A1 (en) | 2018-05-24 | 2019-11-28 | 3M Innovative Properties Company | N-1 branched cycloalkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods |
| CN113166143B (zh) | 2018-11-26 | 2024-06-04 | 舒万诺知识产权公司 | N-1支链烷基醚取代的咪唑并[4,5-c]喹啉化合物、组合物和方法 |
| US20220370606A1 (en) | 2018-12-21 | 2022-11-24 | Pfizer Inc. | Combination Treatments Of Cancer Comprising A TLR Agonist |
| US20220177471A1 (en) | 2019-06-06 | 2022-06-09 | 3M Innovative Properties Company | N-1 branched alkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods |
| EP3983408A1 (en) | 2019-06-12 | 2022-04-20 | 3M Innovative Properties Company | Phenethyl substituted imidazo[4,5-c]quinoline compounds with an n-1 branched group |
| WO2021116420A1 (en) | 2019-12-13 | 2021-06-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of tlr7 and/or tlr8 agonists for the treatment of leptospirosis |
| WO2021124073A1 (en) | 2019-12-17 | 2021-06-24 | Pfizer Inc. | Antibodies specific for cd47, pd-l1, and uses thereof |
| WO2022009157A1 (en) | 2020-07-10 | 2022-01-13 | Novartis Ag | Lhc165 and spartalizumab combinations for treating solid tumors |
| KR20230022246A (ko) | 2020-07-17 | 2023-02-14 | 화이자 인코포레이티드 | 치료 항체 및 그의 용도 |
Family Cites Families (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3314941A (en) | 1964-06-23 | 1967-04-18 | American Cyanamid Co | Novel substituted pyridodiazepins |
| US3764681A (en) * | 1970-07-08 | 1973-10-09 | Lilly Co Eli | Certain tetrazolo-(1,5-a) quinoline compounds as fungus control agents |
| US3917624A (en) | 1972-09-27 | 1975-11-04 | Pfizer | Process for producing 2-amino-nicotinonitrile intermediates |
| IL73534A (en) * | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
| ZA848968B (en) | 1983-11-18 | 1986-06-25 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines |
| US5238944A (en) | 1988-12-15 | 1993-08-24 | Riker Laboratories, Inc. | Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine |
| US5756747A (en) | 1989-02-27 | 1998-05-26 | Riker Laboratories, Inc. | 1H-imidazo 4,5-c!quinolin-4-amines |
| US5037986A (en) | 1989-03-23 | 1991-08-06 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo[4,5-c]quinolin-4-amines |
| US4929624A (en) * | 1989-03-23 | 1990-05-29 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo(4,5-c)quinolin-4-amines |
| NZ232740A (en) | 1989-04-20 | 1992-06-25 | Riker Laboratories Inc | Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster |
| US4988815A (en) | 1989-10-26 | 1991-01-29 | Riker Laboratories, Inc. | 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines |
| ES2071340T3 (es) | 1990-10-05 | 1995-06-16 | Minnesota Mining & Mfg | Procedimiento para la preparacion de imidazo(4,5-c)quinolin-4-aminas. |
| US5389640A (en) | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| US5175296A (en) | 1991-03-01 | 1992-12-29 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-c]quinolin-4-amines and processes for their preparation |
| US5268376A (en) * | 1991-09-04 | 1993-12-07 | Minnesota Mining And Manufacturing Company | 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| US5378698A (en) * | 1991-10-21 | 1995-01-03 | Shionogi & Co., Ltd. | Benzothiazepine derivatives |
| US5266575A (en) * | 1991-11-06 | 1993-11-30 | Minnesota Mining And Manufacturing Company | 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines |
| IL105325A (en) | 1992-04-16 | 1996-11-14 | Minnesota Mining & Mfg | Immunogen/vaccine adjuvant composition |
| US5395937A (en) | 1993-01-29 | 1995-03-07 | Minnesota Mining And Manufacturing Company | Process for preparing quinoline amines |
| JPH09500128A (ja) | 1993-07-15 | 1997-01-07 | ミネソタ マイニング アンド マニュファクチャリング カンパニー | イミダゾ〔４，５−ｃ〕ピリジン−４−アミン |
| US5648516A (en) | 1994-07-20 | 1997-07-15 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
| US5352784A (en) | 1993-07-15 | 1994-10-04 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
| US5644063A (en) | 1994-09-08 | 1997-07-01 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-c]pyridin-4-amine intermediates |
| US5482936A (en) * | 1995-01-12 | 1996-01-09 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-C]quinoline amines |
| US5585612A (en) | 1995-03-20 | 1996-12-17 | Harp Enterprises, Inc. | Method and apparatus for voting |
| JPH09208584A (ja) | 1996-01-29 | 1997-08-12 | Terumo Corp | アミド誘導体、およびそれを含有する医薬製剤、および合成中間体 |
| JPH09255926A (ja) | 1996-03-26 | 1997-09-30 | Diatex Co Ltd | 粘着テープ |
| US5693811A (en) | 1996-06-21 | 1997-12-02 | Minnesota Mining And Manufacturing Company | Process for preparing tetrahdroimidazoquinolinamines |
| US5741908A (en) * | 1996-06-21 | 1998-04-21 | Minnesota Mining And Manufacturing Company | Process for reparing imidazoquinolinamines |
| DE69737935T2 (de) | 1996-10-25 | 2008-04-03 | Minnesota Mining And Manufacturing Co., St. Paul | Die Immunantwort modifizierende Verbindung zur Behandlung von durch TH2 vermittelten und verwandten Krankheiten |
| PT839810E (pt) * | 1996-11-04 | 2003-01-31 | Bayer Cropscience Sa | 1-poliarilpirazois como pesticidas |
| US5939090A (en) | 1996-12-03 | 1999-08-17 | 3M Innovative Properties Company | Gel formulations for topical drug delivery |
| US6069149A (en) | 1997-01-09 | 2000-05-30 | Terumo Kabushiki Kaisha | Amide derivatives and intermediates for the synthesis thereof |
| UA67760C2 (uk) * | 1997-12-11 | 2004-07-15 | Міннесота Майнінг Енд Мануфакчурінг Компані | Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки |
| JPH11222432A (ja) | 1998-02-03 | 1999-08-17 | Terumo Corp | インターフェロンを誘起するアミド誘導体を含有する外用剤 |
| JPH11255926A (ja) | 1998-03-13 | 1999-09-21 | Toray Ind Inc | シリコーン成型品およびその製造方法 |
| US6110929A (en) | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
| JP2000119271A (ja) | 1998-08-12 | 2000-04-25 | Hokuriku Seiyaku Co Ltd | １ｈ―イミダゾピリジン誘導体 |
| US6518280B2 (en) * | 1998-12-11 | 2003-02-11 | 3M Innovative Properties Company | Imidazonaphthyridines |
| US20020058674A1 (en) * | 1999-01-08 | 2002-05-16 | Hedenstrom John C. | Systems and methods for treating a mucosal surface |
| EP1140091B1 (en) | 1999-01-08 | 2005-09-21 | 3M Innovative Properties Company | Formulations comprising imiquimod or other immune response modifiers for treating cervical dysplasia |
| US6545485B1 (en) * | 1999-01-21 | 2003-04-08 | Radar Engineers | Ultrasonic pinpointer for power system sources of interference |
| US6558951B1 (en) * | 1999-02-11 | 2003-05-06 | 3M Innovative Properties Company | Maturation of dendritic cells with immune response modifying compounds |
| JP2000247884A (ja) | 1999-03-01 | 2000-09-12 | Sumitomo Pharmaceut Co Ltd | アラキドン酸誘発皮膚疾患治療剤 |
| US6331539B1 (en) * | 1999-06-10 | 2001-12-18 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
| US6756382B2 (en) * | 1999-06-10 | 2004-06-29 | 3M Innovative Properties Company | Amide substituted imidazoquinolines |
| US6573273B1 (en) * | 1999-06-10 | 2003-06-03 | 3M Innovative Properties Company | Urea substituted imidazoquinolines |
| US6541485B1 (en) | 1999-06-10 | 2003-04-01 | 3M Innovative Properties Company | Urea substituted imidazoquinolines |
| US6451810B1 (en) | 1999-06-10 | 2002-09-17 | 3M Innovative Properties Company | Amide substituted imidazoquinolines |
| US6660260B1 (en) * | 1999-09-21 | 2003-12-09 | Mayo Foundation For Medical Education And Research | Bioprosthetic heart valves |
| US6376669B1 (en) | 1999-11-05 | 2002-04-23 | 3M Innovative Properties Company | Dye labeled imidazoquinoline compounds |
| US6894060B2 (en) | 2000-03-30 | 2005-05-17 | 3M Innovative Properties Company | Method for the treatment of dermal lesions caused by envenomation |
| US20020055517A1 (en) | 2000-09-15 | 2002-05-09 | 3M Innovative Properties Company | Methods for delaying recurrence of herpes virus symptoms |
| JP2002145777A (ja) | 2000-11-06 | 2002-05-22 | Sumitomo Pharmaceut Co Ltd | アラキドン酸誘発皮膚疾患治療剤 |
| US6664260B2 (en) * | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Heterocyclic ether substituted imidazoquinolines |
| US6664264B2 (en) * | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
| US6677347B2 (en) * | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamido ether substituted imidazoquinolines |
| US6660735B2 (en) * | 2000-12-08 | 2003-12-09 | 3M Innovative Properties Company | Urea substituted imidazoquinoline ethers |
| US6664265B2 (en) * | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
| US6545016B1 (en) | 2000-12-08 | 2003-04-08 | 3M Innovative Properties Company | Amide substituted imidazopyridines |
| UA74593C2 (en) | 2000-12-08 | 2006-01-16 | 3M Innovative Properties Co | Substituted imidazopyridines |
| US6525064B1 (en) | 2000-12-08 | 2003-02-25 | 3M Innovative Properties Company | Sulfonamido substituted imidazopyridines |
| US6660747B2 (en) * | 2000-12-08 | 2003-12-09 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
| AU3249802A (en) * | 2000-12-08 | 2002-06-18 | 3M Innovative Properties Co | Screening method for identifying compounds that selectively induce interferon alpha |
| US6545017B1 (en) | 2000-12-08 | 2003-04-08 | 3M Innovative Properties Company | Urea substituted imidazopyridines |
| UA74852C2 (en) * | 2000-12-08 | 2006-02-15 | 3M Innovative Properties Co | Urea-substituted imidazoquinoline ethers |
| US6667312B2 (en) * | 2000-12-08 | 2003-12-23 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
| US6677348B2 (en) * | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Aryl ether substituted imidazoquinolines |
| CA2449754A1 (en) | 2001-06-15 | 2002-12-27 | 3M Innovative Properties Company | Immune response modifiers for the treatment of periodontal disease |
| WO2003020889A2 (en) | 2001-08-30 | 2003-03-13 | 3M Innovative Properties Company | Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules |
| US6667347B2 (en) * | 2001-09-14 | 2003-12-23 | Chevron U.S.A. Inc. | Scrubbing CO2 from methane-containing gases using an aqueous stream |
| WO2003094836A2 (en) * | 2001-10-12 | 2003-11-20 | University Of Iowa Research Foundation | Methods and products for enhancing immune responses using imidazoquinoline compounds |
| US20040014779A1 (en) * | 2001-11-16 | 2004-01-22 | 3M Innovative Properties Company | Methods and compositions related to IRM compounds and toll-like recptor pathways |
| CA2467828C (en) * | 2001-11-29 | 2011-10-04 | 3M Innovative Properties Company | Pharmaceutical formulations comprising an immune response modifier |
| US6677349B1 (en) * | 2001-12-21 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
| SI1478327T1 (sl) * | 2002-02-22 | 2015-08-31 | Meda Ab | Metoda za zmanjšanje in zdravljenje imunosupresije, inducirane z UV-B |
| GB0211649D0 (en) | 2002-05-21 | 2002-07-03 | Novartis Ag | Organic compounds |
| WO2003101949A2 (en) * | 2002-05-29 | 2003-12-11 | 3M Innovative Properties Company | Process for imidazo[4,5-c]pyridin-4-amines |
| AU2003237386A1 (en) * | 2002-06-07 | 2003-12-22 | 3M Innovative Properties Company | Ether substituted imidazopyridines |
| WO2004032829A2 (en) * | 2002-08-15 | 2004-04-22 | 3M Innovative Properties Company | Immunostimulatory compositions and methods of stimulating an immune response |
| US6818650B2 (en) * | 2002-09-26 | 2004-11-16 | 3M Innovative Properties Company | 1H-imidazo dimers |
| EP1572236A4 (en) * | 2002-11-14 | 2007-01-03 | Pintex Pharmaceuticals Inc | PINE RATE1 IN HEALTHY FABRIC AND IN CANCER FABRIC |
| AU2003287316A1 (en) * | 2002-12-11 | 2004-06-30 | 3M Innovative Properties Company | Assays relating to toll-like receptor activity |
| AU2003287324A1 (en) * | 2002-12-11 | 2004-06-30 | 3M Innovative Properties Company | Gene expression systems and recombinant cell lines |
| EP1590348A1 (en) * | 2002-12-20 | 2005-11-02 | 3M Innovative Properties Company | Aryl / hetaryl substituted imidazoquinolines |
| JP2006512391A (ja) * | 2002-12-30 | 2006-04-13 | スリーエム イノベイティブ プロパティズ カンパニー | 組み合わせ免疫賦活薬 |
| WO2004071459A2 (en) * | 2003-02-13 | 2004-08-26 | 3M Innovative Properties Company | Methods and compositions related to irm compounds and toll-like receptor 8 |
| EP1599726A4 (en) * | 2003-02-27 | 2009-07-22 | 3M Innovative Properties Co | SELECTIVE MODULATION OF TLR-MEDIATED BIOLOGICAL ACTIVITY |
| AU2004218349A1 (en) * | 2003-03-04 | 2004-09-16 | 3M Innovative Properties Company | Prophylactic treatment of UV-induced epidermal neoplasia |
| CA2517655A1 (en) * | 2003-03-07 | 2004-09-23 | 3M Innovative Properties Company | 1-amino 1h-imidazoquinolines |
| US8426457B2 (en) * | 2003-03-13 | 2013-04-23 | Medicis Pharmaceutical Corporation | Methods of improving skin quality |
| AU2004220465A1 (en) * | 2003-03-13 | 2004-09-23 | 3M Innovative Properties Company | Method of tattoo removal |
| US7699057B2 (en) * | 2003-03-13 | 2010-04-20 | 3M Innovative Properties Company | Methods for treating skin lesions |
| US20040192585A1 (en) * | 2003-03-25 | 2004-09-30 | 3M Innovative Properties Company | Treatment for basal cell carcinoma |
| US20040191833A1 (en) * | 2003-03-25 | 2004-09-30 | 3M Innovative Properties Company | Selective activation of cellular activities mediated through a common toll-like receptor |
| AU2004244962A1 (en) * | 2003-04-10 | 2004-12-16 | 3M Innovative Properties Company | Delivery of immune response modifier compounds using metal-containing particulate support materials |
| EP1617845A4 (en) * | 2003-04-28 | 2006-09-20 | 3M Innovative Properties Co | COMPOSITIONS AND METHODS FOR INDUCING OPOID RECEPTORS |
| OA13310A (en) * | 2003-09-05 | 2007-04-13 | Anadys Pharmaceuticals Inc | TLR7 ligands for the treatment of hepatitis C. |
| AR052447A1 (es) * | 2004-12-30 | 2007-03-21 | 3M Innovative Properties Co | Etansulfonato de 1-(2-metipropil)-1h-imidazo[4,5-c] [1,5] naftiridin-4- amina y metansulfonato de 1-(2- metipropil)-1h-imidazo[4,5 -c] [1,5] naftiridin-4-amina |
-
1998
- 1998-11-12 UA UA2000074070A patent/UA67760C2/uk unknown
- 1998-12-11 DE DE69835844T patent/DE69835844T2/de not_active Expired - Fee Related
- 1998-12-11 AT AT04022440T patent/ATE333456T1/de active
- 1998-12-11 DE DE69826518T patent/DE69826518T2/de not_active Expired - Fee Related
- 1998-12-11 KR KR1020037016103A patent/KR100563175B1/ko not_active IP Right Cessation
- 1998-12-11 ES ES04022440T patent/ES2270249T3/es not_active Expired - Lifetime
- 1998-12-11 RU RU2003126258/04A patent/RU2314307C2/ru active
- 1998-12-11 DK DK04022441T patent/DK1512686T3/da active
- 1998-12-11 SI SI9830868T patent/SI1512686T1/sl unknown
- 1998-12-11 AU AU19123/99A patent/AU753864B2/en not_active Ceased
- 1998-12-11 HU HU0101155A patent/HUP0101155A3/hu unknown
- 1998-12-11 SK SK835-2000A patent/SK285872B6/sk not_active IP Right Cessation
- 1998-12-11 RU RU2000114496/04A patent/RU2221798C2/ru active
- 1998-12-11 SK SK5035-2007A patent/SK286304B6/sk not_active IP Right Cessation
- 1998-12-11 KR KR1020037016102A patent/KR100642702B1/ko not_active IP Right Cessation
- 1998-12-11 CA CA2311456A patent/CA2311456C/en not_active Expired - Lifetime
- 1998-12-11 NZ NZ504776A patent/NZ504776A/en unknown
- 1998-12-11 DE DE69835309T patent/DE69835309T2/de not_active Expired - Lifetime
- 1998-12-11 KR KR1020007006369A patent/KR100642703B1/ko not_active IP Right Cessation
- 1998-12-11 WO PCT/US1998/026473 patent/WO1999029693A1/en active Application Filing
- 1998-12-11 PT PT04022440T patent/PT1512685E/pt unknown
- 1998-12-11 EE EEP200000349A patent/EE04314B1/xx not_active IP Right Cessation
- 1998-12-11 US US09/210,114 patent/US6194425B1/en not_active Expired - Fee Related
- 1998-12-11 PL PL98341159A patent/PL193915B1/pl not_active IP Right Cessation
- 1998-12-11 ES ES04022441T patent/ES2273138T3/es not_active Expired - Lifetime
- 1998-12-11 AT AT04022441T patent/ATE338757T1/de not_active IP Right Cessation
- 1998-12-11 PT PT04022441T patent/PT1512686E/pt unknown
- 1998-12-11 BR BR9814275-5A patent/BR9814275A/pt not_active IP Right Cessation
- 1998-12-11 CN CNB988135639A patent/CN1154647C/zh not_active Expired - Fee Related
- 1998-12-11 EP EP98963888A patent/EP1040112B1/en not_active Expired - Lifetime
- 1998-12-11 JP JP2000524286A patent/JP4283438B2/ja not_active Expired - Fee Related
- 1998-12-11 CZ CZ2007-268A patent/CZ307184B6/cs not_active IP Right Cessation
- 1998-12-11 ES ES98963888T patent/ES2227902T3/es not_active Expired - Lifetime
- 1998-12-11 IL IL13655698A patent/IL136556A0/xx active IP Right Grant
- 1998-12-11 AT AT98963888T patent/ATE277046T1/de not_active IP Right Cessation
- 1998-12-11 RU RU2003126259/04A patent/RU2312867C2/ru not_active IP Right Cessation
- 1998-12-11 PT PT98963888T patent/PT1040112E/pt unknown
- 1998-12-11 TR TR2000/01705T patent/TR200001705T2/xx unknown
-
2000
- 2000-05-24 NO NO20002663A patent/NO316687B1/no not_active IP Right Cessation
- 2000-06-02 HR HR20000363A patent/HRP20000363B1/xx not_active IP Right Cessation
- 2000-06-05 IL IL136556A patent/IL136556A/en not_active IP Right Cessation
- 2000-11-06 US US09/706,990 patent/US6514985B1/en not_active Expired - Fee Related
-
2001
- 2001-08-31 US US09/945,197 patent/US6624172B2/en not_active Expired - Lifetime
-
2002
- 2002-06-27 US US10/185,387 patent/US6693113B2/en not_active Expired - Lifetime
- 2002-06-27 US US10/184,304 patent/US6638944B2/en not_active Expired - Fee Related
- 2002-10-07 US US10/265,956 patent/US6699878B2/en not_active Expired - Fee Related
-
2003
- 2003-04-02 US US10/405,321 patent/US6747040B2/en not_active Expired - Fee Related
- 2003-04-03 US US10/406,181 patent/US6797716B2/en not_active Expired - Lifetime
- 2003-12-19 NO NO20035718A patent/NO328045B1/no not_active IP Right Cessation
- 2003-12-19 NO NO20035719A patent/NO20035719D0/no unknown
-
2004
- 2004-04-14 US US10/824,232 patent/US6894165B2/en not_active Expired - Fee Related
- 2004-12-03 US US11/004,674 patent/US6949646B2/en not_active Expired - Lifetime
-
2005
- 2005-04-21 HK HK05103436A patent/HK1070655A1/xx not_active IP Right Cessation
- 2005-07-25 US US11/188,418 patent/US7038051B2/en not_active Expired - Lifetime
- 2005-12-12 JP JP2005358302A patent/JP4203067B2/ja not_active Expired - Fee Related
-
2006
- 2006-02-13 US US11/276,074 patent/US7335773B2/en not_active Expired - Fee Related
- 2006-09-14 IL IL178092A patent/IL178092A/en not_active IP Right Cessation
- 2006-09-14 IL IL178091A patent/IL178091A/en not_active IP Right Cessation
-
2007
- 2007-03-28 US US11/692,701 patent/US20070167481A1/en not_active Abandoned
- 2007-07-11 JP JP2007181872A patent/JP2007262093A/ja not_active Withdrawn
- 2007-12-06 US US11/999,602 patent/US7678918B2/en not_active Expired - Fee Related
- 2007-12-26 JP JP2007335120A patent/JP2008115190A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1512686T3 (da) | Imidazonaphtyridiner og deres anvendelse til at inducere cytokinbiosyntese | |
| ATE320435T1 (de) | Oxazolo-, thiazolo- und selenazolo-(4,5- c)naphthyridin-4-amine und analoge davon | |
| ATE333284T1 (de) | Verfahren mittels durch nukleinsäuren induziertes immunostimulatorisches interferon | |
| HUP0300005A2 (hu) | Módosított citokinek a rák kezelésében | |
| WO2003022225A3 (en) | Compositions comprising mixtures of therapeutic proteins and methods of producing the same | |
| WO2004041297A3 (en) | Modified cytokines for use in cancer therapy | |
| EP1423693A4 (en) | COMBINATION THERAPY WITH ERYTHROPOETIN AND ANTI-TUMORNEKROSE FACTOR ALPHA |